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INTRODUCTION 
 
Since its development as a sub-speciality within radiology, Interventional Radiology (IR) 
has played an increasingly important role in caring for the patient with cancer. This role 
begins with initial diagnosis of cancer and involvement now extends into minimally 
invasive treatment of malignancy alone or in combination with other treatment modalities. 
IR has established a very important role in the management of complications incurred 
during many oncological treatments. This chapter provides an updated overview of the 
scope of IR in the management of the oncology patient. 
  
INTERVENTIONAL RADIOLOGY IN THE DIAGNOSIS OF CANCER 
 
Biopsy 
In the modern era, the Interventional Radiologist utilises an expanding range of imaging 
modalities, either alone or in combination, to assess the appropriateness of percutaneous 
biopsy in individual cases, to obtain a histological diagnosis and or definitively stage 
malignant disease. The modern interventionalist, therefore, requires skills in interpretation 
of modern cross-sectional imaging techniques to ensure that percutaneous biopsy is 
indicated, that the correct lesion is biopsied when there are multiple lesions, and to offer an 
opinion regarding future management when histological diagnosis based on percutaneous 
biopsy would not appear representative of imaging appearances.   
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Percutaneous biopsy was first described by Leiden in 1883 when the procedure was utilised 
to sample the causative micro organisms of pneumonia1.  Percutaneous biopsy has been 
applied in most organ systems with excellent results and few complications2.  
 
The key to successful and safe biopsy is the use of image guidance which facilitates safe 
passage of needle into an organ or mass to facilitate histological or cytological analysis2.  
In oncology patients with febrile neutropenia, percutaneous biopsy is also increasingly 
being performed for microbiologic analysis of lesions within organs such as lung or liver 
suspicious for opportunistic infections such as fungal infection.   
 
With regard to choice of image-modality to guide percutaneous biopsy, ultrasound (US) 
has the advantage of real-time imaging, allowing accurate monitoring of the needle 
trajectory as it traverses tissues en route to the target lesion3 .  When a lesion is visible by 
ultrasound, with appropriate ultrasound equipment and operator experience, this modality 
offers much better real-time imaging than CT3   In addition, the use of US avoids radiation 
exposure to patients and staff during the course of a biopsy.  The use of CT has the benefit 
of precise needle localization and better localisation of regional anatomy when compared 
with US3 (Figure 1). This is particularly important in the case of pelvic or retroperitoneal 
biopsies which can frequently be difficult to perform using US guidance. The use of CT, 
has the disadvantage of increased procedure duration and associated radiation dose to 
patient and staff.   The utilisation of CT fluoroscopy allows near real-time imaging of 
needle trajectory.  CT fluoroscopy, when appropriately utilized can reduce the radiation 
dose associated with CT guided biopsy by reducing the duration of the procedure and also 
  
3 
CT fluoroscopic images can be acquired using lower milliamperage (mA) .  One of the 
potential disadvantages of the utilisation of CT fluoroscopy is increased radiation exposure 
to physician and staff assisting during the procedure.   
 
Contraindications to percutaneous needle biopsy include coagulation defects which can 
increase the risk of bleeding following the procedure or lack of a safe access to the lesion2.  
For biopsy of intrabdominal or pelvic lesions, traversing bowel should be avoided.  There 
are relative contra-indications which are specific to individual organ biopsies such as 
severe emphysema, pulmonary hypertension or previous pneumonectomy in the case of 
percutaneous lung biopsy.  In these situations, the benefits of the procedure need to be 
weighed against the risks and discussion and consensus at multidisciplinary meetings is 
extremely helpful.   Once it has been decided that the risk:benefit ratio is acceptable, a 
number of physiological parameters need to be measured and corrected in order to 
adequately prepare a patient for the procedure. 
 
The pathological samples obtained using IR take one of two main forms; histological and 
cytological. In general, the yield from cytology is less than that of histology. Although 
larger specimens are preferred where possible, the size of the sample that can be obtained 
depends on the size and location of the mass. In general, at our institution, visceral biopsies 
with the exception of lung biopsies are performed using a 17gauge/18 gauge co-axial 
needle system. For percutaneous lung biopsy we use a 19 gauge/20 gauge co-axial needle 
system. 
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In selected cases, with appropriate lesion selection, percutaneous biopsy can not only 
establish histological diagnosis but in addition, can facilitate staging of disease.  For 
example if a patient has a malignant-appearing lung lesion in the presence of a liver or 
adrenal lesion, biopsy of the liver or adrenal lesion can establish histological diagnosis and 
stage the patient at the same time(Figure 2).  
 
Complications of Biopsy 
Many of the complications described following percutaneous needle biopsy are common to 
biopsy of any organ and include bleeding and infection.  Other complications are specific 
to the organ being biopsied such as pneumothorax and hemoptysis following lung biopsy, 
bowel perforation following pelvic mass biopsy and hematuria, urinary retention and 
prostatitis following transrectal prostate biopsy. Appropriate informed consent should 
include a description of common complications specific to the biopsy being performed.  
The accepted incidences of complications following a range of IR procedures, including 
percutaneous biopsy has been reported by the Society of Interventional Radiology (SIR)2 
Incidences of complications, however, can vary between institutions, depending on severity 
of disease in patient population being treated and the incidence of co-morbidity. 
Institutional audit should be performed and complication rates should be compared with 
threshold incidence values which have been calculated for each procedure.  
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INTERVENTIONAL RADIOLOGY IN THE TREATMENT OF CANCER 
 
Interventional Radiology may be used in a multidisciplinary setting to assist in the 
management and treatment of cancer. Perhaps the most common means by which IR can 
facilitate patient treatment is by the provision of image guided central venous access. In 
addition, IR procedures are currently expanding the range of oncological therapies. These 
procedures are generally less invasive than surgery and are therefore considered minimally 
invasive. Chemotherapy agents can be selectively administered as part of 
chemoembolization procedures and focused treatments using thermal ablation and gene 
therapy may be administered in the appropriate setting using image guidance. 
 
Central Venous Catheters 
Central venous catheters (CVC) provide a means of administering medications or 
parenteral nutrition to patients. There are 4 main types of CVC device. Temporary 
peripheral and central non-tunnelled catheters, tunnelled central catheters and implanted 
devices. Over 200,000 central access devices are inserted per year in the UK4. Although 
these devices have been inserted by anaesthetists and surgeons in the past, these devices are 
now commonly inserted using IR5. This is because real time imaging guidance of the 
needle or catheter either by radiological screening or ultrasound reduces the incidence of 
complications related to insertion6. For these reasons central venous access using 
ultrasound guidance is recommended by the national institute for clinical excellence in the 
UK since 2002. The right internal jugular vein is the most commonly used central access 
portal7.  Complications related to central venous access procedures are dependent on choice 
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of access route and are impacted by patient selection8. Complications that occur at the time 
of insertion are typically related to injury to surrounding structures or mal-position of 
catheter and occur less commonly when performed with image-guidance than when 
performed blindly or using external landmarks8. 
 
Thrombosis 
In addition, IR has the ability to diagnose complications related to insertion such as 
thrombosis and IR can also map alternative access sites in difficult cases. The common 
long term complications associated with central venous catheter (CVC) placement are 
thrombosis and infection. The overall long-term incidence of central venous thrombosis is 
between 30% and 70%9, 10. Trauma to the endothelium from the catheter tip is believed to 
cause the accumulation of thrombus11. Although the incidence of symptomatic CVC 
thromboembolism is less than 5%, asymptomatic thrombosis frequently occurs. Larger 
catheters with more lumens and catheters inserted into left sided veins are associated with 
an increased risk of thrombosis as is catheter insertion in patients with inherited 
prothrombotic tendencies10. Thrombosis is a potentially serious complication. It is the 
second leading cause of death in patients with cancer and 1 in 7 cancer patients who die in 
hospital do so as a result of venous thromboembolism12. Unfortunately thrombotic 
prophylaxis using low dose warfarin and heparin have not been shown to reduce the 
incidence of CVC thrombosis13. Satisfactory data pertaining to the treatment of catheter 
related thrombosis are lacking. No uniformly accepted method of anticoagulation or 
duration of such treatments exists. 
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Infection 
Nosocomial infection introduced at the time of catheter insertion is an important source of 
patient morbidity. Efforts to reduce the incidence of infection have concentrated on asepsis 
at the time of insertion and careful skin preparation14. Up to 20% of patients with catheter-
related blood borne infections die. One third of these deaths are directly attributable to 
catheter-related infection14. Catheter-related infections should be diagnosed by paired 
quantitative blood cultures. In the absence of shock, local infection or septic 
thrombophlebitis, a tunneled CVC with an external access device may be left in situ and 
the infection treated with parenteral antibiotics15. The deposition of infected clots within 
port devices means that once infected removal of the device will required15. 
 
Embolisation 
Minimally invasive image guided cancer treatments as an alternative or adjunct to surgery 
are currently under development. These cancer treatments consist of image guided 
procedures which sometimes require more than one IR session to compete therapy. 
Chemoembolization, radionuclide ablation and thermal ablation are being performed at 
present. Following contrast enhanced CT or MRI, transcatheter embolization may be 
performed in order to devascularise neoplastic tissue by occluding tumour arterial supply16. 
Mechanical occlusion is achieved using Gelfoam (Pharmacia & Upjohn, Kalamazoo, MI), 
polyvinyl alcohol or blood clots. These materials are introduced into the tumour bed 
following fluouroscopic guided selective arterial catheterisation by IR. Angiographic 
experience particularly with embolization techniques and in-depth knowledge of normal 
and variant anatomy relevant to the procedure are vital before embarking on these 
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techniques.  These techniques can be used as the primary modality of treatment of hepatic 
metastases or in conjunction with ablative treatments or conventional surgery.  Arterial 
embolization can also be employed prior to surgical resection in an effort to reduce 
operative blood losses particularly when tumours appear hypervascular on preoperative 
imaging. Palliative embolization of inoperable tumours may also reduce tumour burden and 
help treat symptoms. This is most commonly performed to assist in the treatment of hepatic 
disease.  
 
For palliative treatment of hepatic disease, embolization materials may be administered in 
combination with chemotherapy agents and ethiodized oil (Ethiodol: Savage, Melville, 
NY). The term “chemoembolization” is used to describe this procedure17. Hepatic tumours 
rely on the hepatic artery for most of their blood supply. This has been demonstrated using 
radio-labelled albumen which quantified tumour uptake of radioisotope infused through the 
hepatic artery compared to the portal vein. The uptake of radioisotope was ten-fold greater 
following hepatic arterial infusion than following portal vein infusion18. Embolization of 
the hepatic artery allows chemotherapy agents to dwell within a target tumour for a longer 
period of time than infusion of a chemotherapy agent alone. This technique has been used 
successfully in the treatment of hepatocellular carcinoma (HCC), hypervascular metastases 
(ocular melanoma) and hepatic endocrine metastases.  
 
Hepatic transplantation for patients with HCC, when there is a single tumour measuring 
less than 5 cm in size or 2 tumours each less than 3cm in diameter, results in a 70% 5-year 
survival19. For inoperable disease, the 2-year survival of patients with HCC is improved 
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from 10 % without treatment to 30-40% following transcatheter oil chemoembolization20.  
Significantly increased 2-year survival from 27% to 63% has been demonstrated when 
chemoembolization has been performed by administering doxorubicin with gelatin21. 
Hormonal symptoms caused by endocrine hepatic metastases can be effectively treated 
with chemoembolization when somatostatin agents or other medical manipulations become 
less effective22. It is currently unclear whether chemoembolization is superior to 
embolization in the treatment of hepatic lesions16. The effects of chemotherapy alone 
versus chemotherapy combined with chemoembolization are currently being investigated in 
the setting of hepatic metastases secondary to colorectal carcinoma23.  
  
Since embolization causes tissue necrosis, complications such as sepsis, abscess formation 
and ischemia may occur. Approximately 10% of patients experience complications as a 
result of chemoembolization17. Post-embolization syndrome consists of fever, pain and 
elevated white cell count. This is experienced by large numbers of patients following 
embolization17.  Prior to treating hepatic lesions, bowel preparation, drainage of obstructed 
biliary systems and octreotide administration for carcinoid tumours help to reduce the 
incidence of complications. Chemoembolization requires that the portal vein be patent or at 
least there must be good collateral blood supply to the liver. Otherwise hepatic necrosis is 
likely to occur following treatment. Interestingly periprocedural antibiotics are not a 
uniformly accepted method of reducing gram negative sepsis24. Ischemia of non-target 
organs such as the spine is another potential major complication. The incidence of spinal 
ischemia is reduced by careful planning angiography. 
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Re-imaging should be performed 4-6 weeks following treatment. The absence of arterial 
phase enhancement of a lesion which was hypervascular on pre-procedural imaging is 
suggestive of successful treatment.  Nodular enhancement of the portal vein and the 
appearance of an enhancing lesion usually signify residual disease. Treatment may involve 
a number of sessions until the entire tumour bed is devascularised. The ability to repeat 
treatments is an advantage of chemoembolization over surgical options.  
 
Radioembolization of tumours is another modality of treatment that may be administered 
through a carefully placed catheter using IR. This method had not gained widespread 
recognition but offers the potential for focused treatment particularly of primary and 
secondary hepatic malignancies. Microspheres composed of glass, albumen or resin may be 
combined with radionuclides such as yttrium 90, rhenium or holmium and introduced 
directly into a tumour mass25. The type of radioisotope that is best suited to treating a 
tumour will depend on the nature of the tumour. These radioisotopes are beta radiation 
emitters. This form of radiation has a very low penetrating power and its necrosing effects 
are localised. The emission of some gamma radiation is desirable as gamma radiation can 
penetrate the body facilitating detection by a gamma camera.  Gamma radiation allows the 
distribution of the radiolabelled particles to be assessed. The efficacy of radioembolization 
has yet to be determined by randomised control trials, however, accurate IR transcatheter 
delivery has shown to be safe and preliminary results confirm its efficacy26. 
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Thermal Ablation 
In addition to chemoembolization and radioembolization, tumour necrosis may also be 
achieved using a variety of thermal ablation techniques. These methods include 
radiofrequency (RF), laser, microwave, ultrasound and cryoablation. IR mediated thermal 
ablation induces tumour necrosis by the application of energy. Radiofrequency ablation 
(RFA) is performed by applying electromagnetic energy with a frequency of less than 30 
MHz to a tumour. Most devices apply energy between 375 and 500 kHz27. RFA may be 
administered using monopolar or bipolar energy sources.  
 
The most commonly used devices consist of multitined electrodes which have an umbrella 
appearance, clustered electrodes which consist of multiple internally cooled electrodes that 
are held together as a group and finally perfusion electrodes which allow fluids such as 
hypertonic saline to be instilled into the tissues being treated28. Tissues are heated to 
temperatures in excess of 60 degrees Celsius ensuring cell death. This method has been 
shown to be safe with a mortality rate of 0.3% and the rate of major complications is 
2.2%29. RFA has gained acceptance as a method of treating hepatic and lung disease and is 
being used in the treatment of adrenal, renal and skeletal lesions30, 31, 32. RFA has been 
reported to be effective in treating tumours up to 7cm in size and a 1cm margin of treated 
normal tissue surrounding the tumour is desirable. Other methods of ablation are less 
commonly used than RF33. Laser ablation, focused ultrasound ablation and microwave 
ablation, which uses electromagnetic radiation with a frequency in excess of 30 MHz,  are 
all currently under investigation.  Many of these techniques are still in development and the 
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roles and relative success rates of these modalities in local treatment of malignant lesions at 
different sites have not yet been clearly defined.  
 
The involutional changes that occur following necrosis should be monitored by serial 
imaging following ablation. Specific post-ablation CT and MRI imaging protocols are 
being developed at many institutions in an effort to confirm completeness of ablation and 
to detect residual or recurrent disease34.  
 
Gene Therapy 
Gene therapy for cancer may be performed by stimulating tumoral immune response 
(tumor vaccines, cytokines), reducing the expression of oncogenes, restoring tumour 
suppressor gene function (p53), enhancing chemotherapeutic sensitivity 
(chemoembolization) and by modifying angiogenesis (retroviruses )35. Selective arterial 
embolization following the delivery of genetic agents by IR reduces unwanted side effects 
and increases dwell time, achieving a better genetic transfer rate36. This therapy may be 
performed directly using cytokine and p53 genes, however, DNA crosses cell membranes 
poorly minimizing transfection rates. In order to adequately express a therapeutic molecule 
within a cell, vector agents that carry genetic agents across the cell membrane more 
effectively are required37. Plasmids and phospholipid agents are often used for this purpose 
but because only a small proportion of a plasmid enters the nucleus, it is not incorporated 
into the genome. In addition plasmid mediated delivery is often short-lived. Retroviral, 
adenoviral and Epstein Barr viruses which cannot replicate are not without their limitations 
  
13 
but can achieve greater and longer lasting genetic expression38. Newer therapies are likely 
to focus on these agents as methods of delivery39.   
 
 
INTERVENTIONAL RADIOLOGY IN THE TREATMENT OF THE 
COMPLICATIONS OF ONCOLOGY  
 
Many complications can occur as a result of organ dysfunction induced by malignancy. 
Although these complications can be very debilitating, many are reversible. These patients 
are often in ill health, malnourished and poor operative candidates. Minimally invasive 
methods of treating these complications are provided by IR. For example, obstruction of 
the renal, biliary and gastrointestinal systems may be relieved. Tumours that outgrow their 
blood supply may induce ischemia and necrosis not only inducing pain, but also resulting 
in perforation and occasionally abscess formation. Localised tumor abscess can be treated 
by percutaneous catheter drainage, but patient and referring physicians need to be made 
aware that although such treatments frequently reduce sepsis and alleviate pain and 
discomfort, high volumes of fluid typically drain persistently from these infected tumors 
and frequently the catheter must remain in situ for the remainder of the patient’s life40.  
 
Biliary Obstruction 
In the oncology patient, biliary obstruction can occur as a result of intrinsic obstruction or 
extrinsic compression of the bile ducts.  The majority of patients presenting with malignant 
biliary obstruction have obstructive jaundice due to distal common bile obstruction 
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secondary to pancreatic neoplasm41.  Other causes of malignant obstruction include 
cholangiocarcinoma or metastatic disease.  Obstructive jaundice secondary to metastatic 
disease is usually due to metastatic nodal disease at the liver hilum or in peripancreatic 
nodes.  Unlike distal biliary obstruction which can be treated endoscopically, proximal 
obstruction usually requires percutaneous intervention. Percutaneous transhepatic 
cholangiography (PTC) involves the injection of contrast into an intrahepatic bile duct in 
order to image the biliary tree. Percutaneous transhepatic biliary drainage (PBD) may be 
either external or internal/external if the level of obstruction can be bridged by catheter.  
Percutaneous treatment of biliary lesions is frequently staged requiring several sessions to 
achieve therapeutic goals42.  Currently, metal stents are almost exclusively used for 
malignant disease with a 6 month patency rate of 50%43. In the majority of patients, indices 
of liver function improve following treatment40. 
 
There is a higher incidence of complications associated with PBD performed in patients 
with cancer than in general population44. This possibly relates to the presence of co-
existing immunosuppression.  Patients with cancer can have an incidence of cholangitis 
following PBD of up to 50%45. One third of these infections occur in patients drained 
externally and two-thirds occur in patients drained externally and internally. In addition, 
there is a positive association between the duration of PBD and the development of 
cholangitis46. Unfortunately patients requiring PBD are often in the later stages of their 
disease processes and the median survival following PBD in one series was 57 days among 
patients with pancreatic carcinoma43.  
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Less frequent complications of PBD include catheter dislodgement, occlusion, leakage and 
electrolyte imbalance. Prophylactic antibiotics, effective in combating Escherichia coli, 
Klebsiella, Enterococcus, Streptococcus, Enterobacter and Pseudomonas aeruginosa, 
should be administered prior to percutaneous biliary procedures. In addition, careful 
manipulation of an infected system and avoiding over-distension with contrast also 
decrease the risk of bacteremia47.   PBD can be successfully completed in 95% of patients 
with dilated ducts but this rate falls to 70% for non-dilated ducts40.  Major complications of 
PBD include sepsis, hemorrhage and localized infection/inflammatory process (abscess, 
peritonitis, cholecystitis and pancreatitis) 43. 
 
Renal Obstruction 
The most common renal intervention performed by IR is percutaneous nephrostomy (PCN) 
(Figure 3). The indications for PCN are urinary tract obstruction caused by intrinsic or 
extrinsic ureteral obstruction usually secondary to calculus disease, malignancy or 
iatrogenic causes48.  Emergency PCN may be required for urinary tract sepsis, 
pyonephrosis, deteriorating renal function or metabolic disturbances such as hyperkalemia 
and metabolic acidosis. This procedure reduces the incidence of gram negative septicaemia 
due to renal obstruction and may improve impaired renal function and reduce inpatient 
admission times.  
 
Ureteric obstruction is not infrequent among oncology patients. In one series of 218 
patients requiring PCN, 76 had underlying malignancy49. The most common malignancies 
causing obstruction in this series were cervical and prostate carcinoma. In cases of 
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malignant ureteric obstruction, when retrograde stenting is unsuccessful or is not feasible, 
the ureter can be accessed antegradely through the PCN tract, and once the ureteric stricture 
is crossed, a ureteric stent can be placed.  This may be either a 1 or a 2-step procedure. 
Obstructed renal collecting systems without pyonephrosis are usually suitable for primary 
antegrade stenting as a one-step procedure with success rates of over 80%50. During a 2-
step procedure either a PCN or an internal-external nephroureteral tube is inserted initially 
and a ureteric stent is placed on a subsequent visit to IR department. Retrograde stenting of 
an obstructed renal collecting system has the advantage of avoiding renal puncture. In the 
oncology patient antegrade stenting may be more appropriate because retrograde 
techniques have a failure rate of 27% among oncology patients compared with 6 % among 
patients with benign disease. Failure is most commonly due to distortion of the ureteric 
orifices precluding stent insertion51. Plastic stents are favoured over metal ones because 
they induce less urothelial hyperplasia and they can be easily replaced. This is usually 
necessary every 3 to 6 months52. PCN can be successfully completed in 98-99% of patients. 
The rate of successful completion of PCN in oncology is mainly determined by degree of 
dilatation of collecting system and by patient’s body habitus49.  Common major 
complications of PCN include septic shock and hemorrhage49. 
 
Upper Gastrointestinal Obstruction 
Tumours of the head and neck often preclude oral feeding. Percutaneous gastrostomy or 
gastojejunostomy tubes may be inserted under fluoroscopy guidance as palliative measures 
(Figure 4). These are most commonly performed by IR having fewer complications than 
endoscopically and surgically inserted feeding tubes53. Mild pain during feeding soon after 
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gastrostomy insertion as well as infection are the most common early complications 
described with incidences of 33% and 23%, respectively54,55. The most common long-term 
complication of gastrostomy tube insertion is tube dislodgement. If the gastrostomy tube 
falls out having been in situ for greater than two weeks, a tract has usually formed and it is 
frequently possible to access the tract and reinsert the tube without the need for re-puncture 
of the stomach. There is no significant difference between the complication rates associated 
with gastrostomy and gastrojejunostomy insertion.   
 
There have been reports of decompression IR gastrostomy and gastrojejunostomy insertion 
in patients with malignant small-bowel obstruction.  These cases frequently have peritoneal 
carcinomatosis from malignant disease, with ovarian carcinoma being the most common 
primary tumor.  Ryan et al (1998) reported 45 consecutive patients with metastatic ovarian 
cancer who underwent a radiologic gastrostomy or gastrojejunostomy with gastropexy56. A 
technical success rate of 98% was achieved and it was concluded that radiologic 
gastrostomy and gastrojejunostomy can be performed safely in patients with ascites and 
peritoneal carcinomatosis, if the patients undergo paracentesis first and if the re-
accumulation of ascites is prevented after tube placement. In addition to paracentesis, 
fixation of the stomach to the anterior abdominal wall using gastropexy sutures also plays 
an important role in preventing pericatheter leakage.  
 
Pain 
Pain is a significant cancer related morbidity which is more common in the later stages of 
disease57. Opiates remain the mainstay of pain treatment. In order to reduce unwanted side 
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effects the three-step ladder and medicine rotation methods are used58. With recent 
developments of new procedures, IR is assuming an expanding role in managing cancer 
associated pain.  
 
Vertebroplasty represents a new and effective treatment for vertebral body compression 
fractures refractory to medical therapy. To date, vertebroplasty has mainly been used in the 
treatment of osteoporotic fractures by introducing cement into the fracture thereby 
stabilising it. Osteolytic tumours often fracture resulting in instability and pain. 
Vertebroplasty has been shown to reduce requirements for analgesia and is now being 
utilized in the treatment of vertebral fractures which result form malignant osseous 
infiltration59.  The incidence of major complications is 5% among oncology patients 
compared with an incidence of 1% in the general population60. The most significant 
complications are leakage of cement into the spinal canal, pulmonary embolus and 
pulmonary oedema. Vertebroplasty should relieve pain and improve mobility in 50-60% of 
oncology patients treated. Better results are achieved by treating sub-acute rather than 
chronic fractures61.  
 
Upper abdominal visceral tumours, and specifically pancreatic, gastric, esophageal, 
colorectal, gallbladder and cholangiocarcinoma are frequently associated with abdominal 
pain which is poorly responsive to analgesic therapy62. Celiac ganglion neurolysis and 
nerve block can be performed for palliation of pain, when resistant to analgesics.   The 
success rate of the procedure has been reported to lie between 70-97%61.  Alcohol or 
phenol destroy nerve roots and triamcinalone reversibly blocks nocireceptors. There is 
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controversy regarding timing of celiac plexus block, with some authors recommending that 
these interventions should only be performed in the later stages of disease and others 
arguing that better results have been demonstrated by treating disease in its earlier stage63. 
Successful celiac axis block can be performed using various methods of image guidance. 
CT guided blockade can be performed using an anterior approach or a posterior approach 
and the choice between these approaches is usually dependent on operator experience and 
anatomic considerations in individual patients61,64.  The most common reported minor 
complications are transient diarrhoea and orthostatic hypotension experienced by 73% and 
12% of patients, respectively64.   
 
Although IR may be used to treat oncological pain it is worth noting that IR itself can 
induce pain among patients. The most common procedures which can result in intra-
procedural and post procedural pain include biliary and nephrostomy drainages and 
percutaneous gastrostomy procedures65. It is important that interventional radiologists 
ensure optimal control of pain during interventional procedures and also work within a 
multidisciplinary team to ensure good pain relief following these procedures. 
 
Pleural Space Intervention 
Dyspnoea in the oncology patient is often caused by malignant pleural effusions (MPE) due 
to pleural and lymphatic involvement. These effusions may be treated by therapeutic 
thoracocentesis which can usually be performed as an outpatient procedure or by placement 
of a chest tube which usually requires admission to hospital.  To definitively treat pleural 
effusions which re-accumulate following thoracocentesis or following chest tube removal, 
  
20 
pleurodesis may be performed.  A recent systematic review concluded that available 
evidence supports the need for chemical sclerosants for successful pleurodesis, with talc 
being the sclerosant of choice, and thoracoscopic pleurodesis as the preferred technique for 
pleurodesis based on efficacy66. Pleurodesis through chest tubes placed by IR can be 
performed at the bedside avoiding the need for general anaesthetic.  However, the above 
systematic review suggested that risk of recurrence of pleural effusion was less with 
thoracosopic versus bedside instillation through different sized chest tubes of various 
sclerosants including tetracycline, bleomycin, talc or mustine66.    
 
Venous Thromboembolism 
Inferior vena cava (IVC) filter placement is an accepted method of managing venous 
thromboembolism (VTE) in the oncology patient. These filters are often inserted following 
lower limb deep venous thrombosis (DVT) in patients for whom anticoagulation is 
contraindicated, in whom a complication of anticoagulation has occurred or in whom 
recurrent PE’s occur in spite of adequate anticoagulation67. In the absence of 
anticoagulation, recurrent DVT occurs more commonly in oncologic patients but the 
incidence has been reported to be reduced to 4% with an inferior vena caval filter in situ68. 
Randomized control trails in this field are currently lacking. Although many devices are 
available, empirical use in oncology patients is not supported in the literature at present.   
The technical success of IVC filter placement is greater than 97% in experienced hands67.  
 
Abscess Drainage 
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The percutaneous aspiration and drainage of primary and postoperative abscesses and 
collections in the absence of indications for immediate surgery has helped reduce patient 
morbidity and morality and reduce hospital stay69. The method of imaging used to perform 
these procedures depends on the location of the collection. CT, CT fluoroscopy and 
ultrasound may all be used.  Image-guided needle aspiration of fluid collections in 
oncology is frequently performed to investigate for infection or malignancy.  Infected 
collections or collections causing pain or obstruction of the gastrointestinal, urinary or 
biliary tracts should be treated by image-guided catheter placement40. The incidence of 
complications associated with percutaneous drainage depends on patient health, location 
and nature of collection. It is generally reported to be 10%70. 
 
CONCLUSION 
 
Minimally invasive techniques in the hands of Interventional Radiologists are increasingly 
utilised in the management of oncology patients from initial diagnosis to treatment of 
primary tumor and metastatic disease and to management of cancer-related morbidity and 
complications related to treatment.  The use of IR techniques should be evidence-based to 
ensure optimal outcome following utilization of these techniques in the oncology patient. 
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